Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

Hemophilia A, characterized by absent or ineffective coagulation factor VIII (FVIII), is a serious bleeding disorder that entails severe and potentially life-threatening bleeding events. Current standard therapy still involves replacement of FVIII, but is often complicated by the occurrence of neutr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelbenegger, Georg, Schoergenhofer, Christian, Knoebl, Paul, Jilma, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649063/
https://www.ncbi.nlm.nih.gov/pubmed/32717759
http://dx.doi.org/10.1055/s-0040-1714279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649063/
https://www.ncbi.nlm.nih.gov/pubmed/32717759
http://dx.doi.org/10.1055/s-0040-1714279

Ejemplares similares